Literature DB >> 7544870

Comparative molecular modelling of the Fas-ligand and other members of the TNF family.

M C Peitsch1, J Tschopp.   

Abstract

A number of proteins with significant similarity to the tumour necrosis factor (TNF) have been identified over the last years. Upon interaction with their cognate receptor (members of the TNF-receptor family), all members of this protein family induce either cell death or proliferation/differentiation of the receptor-bearing cells. One of the last identified members of the TNF family is the apoptosis-inducing ligand of the Fas-receptor, termed Fas-ligand (FasL). Here we report the cloning and sequencing of the mouse cDNA for the FasL. Using knowledge-based protein modelling, we demonstrate that all members of the TNF family form trimeric complexes, and define the residues located at the subunit interfaces. The resulting structurally corrected multiple sequence alignment allows the identification of residues potentially involved in receptor recognition, and should help design mutagenesis experiments for structure-function relationship studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544870     DOI: 10.1016/0161-5890(95)00016-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

1.  Arresting and releasing Staphylococcal alpha-hemolysin at intermediate stages of pore formation by engineered disulfide bonds.

Authors:  Toshimitsu Kawate; Eric Gouaux
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

2.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.

Authors:  K V Prasad; Z Ao; Y Yoon; M X Wu; M Rizk; S Jacquot; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Authors:  Nizar M Tannir; Andres Forero-Torres; Radhakrishnan Ramchandren; Sumanta K Pal; Stephen M Ansell; Jeffrey R Infante; Sven de Vos; Paul A Hamlin; Stella K Kim; Nancy C Whiting; Elaina M Gartner; Baiteng Zhao; John A Thompson
Journal:  Invest New Drugs       Date:  2014-08-22       Impact factor: 3.850

5.  Polymorphism of murine Fas ligand that affects the biological activity.

Authors:  N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface.

Authors:  J Bajorath
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

7.  Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.

Authors:  K P MacDonald; Y Nishioka; P E Lipsky; R Thomas
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 8.  Apoptosis in the heart: when and why?

Authors:  H J Brömme; J Holtz
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

9.  Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients.

Authors:  Hanen Ouadani; Imen Ben-Mustapha; Meriem Ben-ali; Leila Ben-khemis; Beya Larguèche; Raoudha Boussoffara; Sonia Maalej; Ilhem Fetni; Saida Hassayoun; Abdelmajid Mahfoudh; Fethi Mellouli; Sadok Yalaoui; Hatem Masmoudi; Mohamed Bejaoui; Mohamed-Ridha Barbouche
Journal:  Immunogenetics       Date:  2015-11-06       Impact factor: 2.846

Review 10.  X-linked immunodeficiency with hyper-IgM (XHIM).

Authors:  L D Notarangelo; A R Hayward
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.